Merah Putih Vaccine Protein Ready for Trials
Domestic Covid-19 vaccine research is progressing. The Eijkamn Institute for Molecular Biology plans to hand over the Red and White vaccine material to Biofarma for pre-clinical and clinical trials.
A number of Eijkman LBM laboratories are operating the Cobas 6800 System machine in the Covid-19 specimen testing laboratory at LBM Eijkman, Jakarta, Thursday (16/7/2020).
JAKARTA, KOMPAS — The Eijkman Molecular Biology Institute has developed a recombinant protein for the Covid-19 vaccine it is striving to develop. This material will be delivered to PT Bio Farma (Persero) at the end of May 2021 for preclinical and clinical trials of the Merah Putih candidate vaccine.
“We have the recombinant protein that will become the Covid-19 vaccine material. Several tests have shown a good response as the antigen stimulates the formation of antibodies,” the head of the Eijkman Molecular Biology Institute, Amin Subandrio, said in Jakarta on Wednesday (21/4/2021).